Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment
Alphyn anticipates the initiation of the global Phase 2b trials of Zabalafin Hydrogel in the first quarter of 2025. Zabalafin Hydrogel has demonstrated strong efficacy and safety in Phase 2a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback